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Abstract
Background: Surgery in Crohn’s disease (CD) may be associated with poor prognosis and clinical and surgical recurrence.
The aim of this study was to describe and compare the post-operative management and outcomes of patients with CD who
underwent first vs recurrent surgeries.
Methods: Observational study that included adult CD patients from 26 Spanish hospitals who underwent ileocolonic resec-
tion with ileocolonic anastomosis between January 2007 and December 2010. Data were retrospectively collected from the
medical records.
Results: Data from 314 patients were analysed, of whom 262 (83%) underwent first surgery and 52 (17%) referred to previous
CD surgeries. Baseline characteristics were similar between the two groups except for a higher rate of stricturing behavior
at diagnosis among re-operated patients (P¼0.03). After surgery, a higher proportion of re-operated patients received
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prophylactic treatment with immunomodulators compared with patients with first surgery (P¼0.04). In re-operated
patients, time to clinical recurrence was not associated with the fact of receiving or not prophylaxis, whereas, in patients
with first surgery, recurrence-free survival was greater when prophylaxis was received (P¼0.03).
Conclusions: After surgery, a higher proportion of patients with previous surgeries received prophylactic treatment with
immunomodulators compared with patients with first surgery. Although prophylactic treatment was beneficial for
preventing clinical recurrence in patients operated on for the first time, it did not significantly reduce the risk of further
recurrence in patients with previous surgeries. This suggests that effective prophylactic therapies are still needed in this
subset of patients.
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Background
Approximately 50% of patients with Crohn’s disease (CD) un-
dergo an intestinal resection within 10 years of diagnosis.
Moreover, about one-fourth of operated patients will undergo a
second surgery within 5 years after the first one [1]. Failure of
medical treatment, stricture, fistula and abscess are the most
common indications for surgery and ileocecal resection is the
most prevalent type of intervention.
CD frequently recurs after an intestinal resection, although
the reported rates of post-operative recurrence vary, depending
on the definition (clinical, endoscopic, radiological or surgical)
[2]. The reported endoscopic recurrence rates at 1 and 3 years
post surgery are 73% and 85%, respectively [3]. The risk of clini-
cal recurrence is estimated to be 20%–25% per year [4]. Previous
studies have reported that new resections were required in
15%–45% of patients at 3 years, in 26%–65% at 10 years and in
33%–82% at 15 years [5].
The high incidence of post-operative recurrence in CD man-
dates a strict follow-up using clinical, biological and imaging
techniques. Several studies tried to identify predictors for
post-operative recurrence. Smoking [6], penetrating disease [7],
perianal disease [8, 9] and extensive (>50-cm) resection [10]
were associated with higher rates of post-operative recurrence,
whereas prophylactic treatment diminished the risk of recur-
rence [11]. Recently, several retrospective studies have shown
that anti-TNF therapy and immunomodulatory therapy, alone
or in combination, seem to be an effective strategy for the
prevention of CD recurrence [12–17].
Limited evidence suggests that multiple CD-related surgeries
may also be a risk factor for worse outcomes and clinical
recurrence at 5 years [18]. The aim of the present study was to
compare the clinical management in real life and the outcomes
of CD patients with only one CD-related intestinal resection
(first surgery group; FSG) with patients who had more than one
surgery (previous surgery group; PSG).
Methods
Study design and patient selection
PRACTICROHN was a retrospective study performed in 26 in-
flammatory bowel disease (IBD) units from Spain that aimed
to explore the outcomes of patients with CD after ileocolonic
surgical resection with ileocolic anastomosis over a period of
3 years–5 years [19]. Patients’ clinical records were the main
source of information; no prospective data collection was
allowed. The study was approved by the corresponding Ethics
Research Committees. In this analysis, we describe and com-
pare the clinical characteristics, management and outcomes of
patients with CD who underwent their first CD-related surgery
vs those who had referred previous surgeries.
Consecutive patients from IBD outpatient clinics aged
18 years who underwent CD-related ileocolonic resection with
ileocolonic anastomosis between January 2007 and December
2010 were identified. All participants signed an informed
consent authorizing the use of their clinical data for research
purposes. For the present analysis, patients’ data from CD diag-
nosis and up to 5 years after surgery were retrieved from the
medical records.
Study variables
The collected data included demographics (age at CD diagnosis
and surgery, gender, smoking status), clinical data (Montreal
classification at diagnosis and at surgery, indication for sur-
gery), treatments received before and after surgery, length of re-
section, length of hospitalization, post-operative complications,
presence of residual disease after surgery, time to follow-up,
prophylaxis for post-operative recurrence and colonoscopy per-
formed within the first year after surgery.
Data regarding prophylaxis, deaths, clinical symptoms of re-
currence, endoscopic results, imaging techniques (computed to-
mography [CT] and magnetic resonance imaging [MRI]),
hospitalizations and re-interventions were collected yearly until
5 years after surgery. In case of multiple surgeries, the surgery
closest to December 2010 was considered the index surgery.
Post-operative clinical recurrence was defined as suggestive
clinical symptoms (diarrhea, abdominal pain) and at least one
of the following: Rutgeert’s endoscopic score i2 and/or confir-
mation of disease activity by CT or MRI performed within
6 months of symptoms. Both endoscopy and imaging techni-
ques were performed according to routine clinical practice and
the investigator’s judgement. Post-operative complications
comprised events recorded until 30 days after surgery and
included death, ileus, anastomotic leak, digestive bleeding,
abscess, wound infection, catheter-related infection and other
extra abdominal infections. Prophylactic treatment for clinical
post-operative recurrence was recorded at discharge or at the
first outpatient visit.
Statistical analysis
Sample size was calculated based on the objective to estimate
the rate of endoscopic recurrence at 52 weeks after surgery,
which had been reported to range between 36% and 56% in pre-
vious studies [15]. For an expected rate of endoscopic recurrence
of 50%, it was necessary to include 267 patients to estimate
the proportion of patients with disease recurrence with a
confidence level of 95% and an accuracy of 6%. The sample size
was increased by 15% (up to 314 individuals) to compensate for
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patients excluded from the analysis due to incomplete data or
other reasons.
Student’s t-test, ANOVA or nonparametric tests (Mann–
Whitney U test) were used to compare continuous variables,
while categorical variables were compared using chi-square test
or Fisher’s exact test. Probability and relative risk were assessed
along with the 95% confidence interval using an exact method.
Missing values and their frequency were tabulated but not in-
cluded in the calculation of percentages. The distribution of the
variables according to theoretical models was verified using the
Kolmogorov–Smirnov test, and the assumption of homogeneity
of variance was assessed using the Levene test. Post-operative
clinical recurrence-free survival was assessed by means of
Kaplan–Meier curves and log-rank tests. Factors associated with
clinical post-operative recurrence were studied using Cox re-
gression analysis. Variables with a P-value <0.15 in the univari-
ate analysis were selected for the multivariate analysis. The
null hypothesis was rejected when P< 0.05.
Results
Patients’ demographic and clinical characteristics
A total of 314 patients were included in the analysis, 52 (17%) of
whom had previous surgeries before the index surgery (50
patients—one previous surgery, one patient—two surgeries and
one patient—three surgeries). Table 1 summarizes patients’ de-
mographic and clinical characteristics. Although most demo-
graphic and clinical characteristics were similar in both study
groups, some differences were observed. Patients in the PSG were
older and had a higher proportion of stricturing disease behavior
at diagnosis, leading to a higher proportion of resection because
of intestinal stenosis. More patients in the PSG had their first sur-
gery in the first 6 months after diagnosis (37% vs 24%, P¼ 0.04). As
expected, the mean disease duration at the time of index surgery
was longer in the PSG than that in the FSG (12 years vs 6 years,
P< 0.001), reflecting a more evolved disease.
Clinical management before surgery and post-operative
complications
Regarding pre-operative treatment, more patients in the PSG
had been exposed to corticosteroids at any time before the in-
dex surgery than in the FSG (P¼ 0.03), although, at the time of
surgery, the concurrent use of corticosteroids was similar be-
tween the two groups (Table 2). Almost 40% of patients were
ever exposed to immunomodulators and one-fourth to anti-
TNF agents at the time of the index surgery, as well as at the
time of surgery, with no differences observed between the study
groups.
A total of 82 (26%) patients experienced post-operative com-
plications, most frequently wound infections, extra-intestinal
infections or anastomotic leak, but no significant differences be-
tween the two groups were found regarding the rate of post-op-
erative complications or length of hospital stay (Table 2).
Clinical management after surgery
After surgery, a total of 208 (68%) patients received prophylactic
treatment for the prevention of post-operative recurrence.
Prophylaxis was prescribed similarly to patients with and with-
out previous surgeries (66% of patients in the FSG and 76% of
Table 1. Demographic and clinical characteristics of patients with Crohn’s disease
Characteristic Total (n¼ 314) First surgery (n¼ 262) Previous surgery (n¼ 52) P-value
Male 151 (48) 132 (50) 19 (37) 0.09
Age at diagnosis, years 28.5 (2–41) 29 (22–42) 27 (22–36) 0.39
16 years 20 (6) 15 (6) 5 (10) 0.36
17–40 years 212 (68) 176 (67) 36 (71)
>40 years 80 (26) 70 (27) 10 (20)
Age at index surgery, years 39 (30–48) 37 (29–48) 41 (34–51) 0.02
Smoking status at surgery 0.48
Smoker 117 (40) 101 (41) 16 (34)
Ex-smoker 63 (21) 50 (20) 13 (28)
Never smoker 114 (39) 96 (39) 18 (38)
Localization at diagnosis 0.70
L1 (6 L4) 183 (59) 154 (59) 29 (57)
L2 (6 L4) 13 (4) 10 (4) 3 (6)
L3 (6 L4) 116 (37) 97 (37) 19 (37)
Behavior at diagnosis 0.03
B1 (6 P) 137 (46) 124 (49) 13 (28)
B2 (6 P) 95 (32) 74 (29) 21 (46)
B3 (6 P) 69 (23) 57 (22) 12 (26)
Indication for surgery 0.09
Penetrating 98 (32) 84 (33) 14 (28)
Stricturing 147 (48) 117 (46) 30 (60)
Penetrating þ stricturing 46 (15) 43 (17) 3 (6)
Resistance to treatment 14 (5) 11 (4) 3 (6)
Time from diagnosis to index surgery, years – 6 6 7 12 6 8 <0.001
First surgery within 6 months from diagnosis 81 (26) 62 (24) 19 (37) 0.04
Values are presented as mean 6 standard deviation, median (range) or N (%).
Missing values were not included in the calculation of percentages.
Location: L1, ileal; L2, colonic; L3, ileocolonic; and L4, isolated upper disease.
Behavior: B1, non-stricturing, non-penetrating; B2, stricturing; B3, penetrating; P, perianal disease modifier.






/gastro/article/7/6/411/5536322 by guest on 25 Septem
ber 2020
patients in the PSG, P¼ 0.20; Table 3). However, a higher propor-
tion of patients in the PSG received prophylactic treatment with
immunomodulators compared to the FSG (59% vs 43%, P¼ 0.04),
whereas antibiotics were used less and only in patients with
first surgery (0% vs 11%, P¼ 0.03).
Time to first control visit and rates of colonoscopies per-
formed during the first year after surgery were similar between
the two cohorts. A similar proportion of patients had residual
disease after the surgery in both cohorts; the post-operative
management of these patients was similar to that of the other
patients (Table 3).
Outcomes after surgery
Within the first year of follow-up, 11 (23%) patients in the PSG
and 62 (24%) patients in the FSG experienced clinical recurrence
(Table 4). When evaluating the effect of previous surgeries on
clinical recurrence-free survival in patients receiving or not pro-
phylaxis, we found no statistical differences (Figure 1).
We also analysed clinical recurrence-free survival according
to the administration of the prophylaxis for post-operative re-
currence. In the FSG, clinical recurrence-free survival time was
longer in patients with prophylactic treatment (P¼ 0.03).
However, there was no significant difference in clinical
recurrence-free survival between patients with and without
prophylaxis in the PSG (P¼ 0.5; Figure 2).
The multivariate Cox regression analysis identified that re-
ceiving no prophylactic treatment or only antibiotic treatment, as
well as the time from diagnosis to surgery, were independent pre-
dictors of post-operative recurrence. Conversely, no residual dis-
ease was associated with less post-operative recurrence (Table 5).
Post-operative endoscopic recurrence (Rutgeert’s score i2)
was observed in 54% at 5 years’ follow-up of all patients, with
similar percentages in both cohorts. A total of 94 (30%) patients








Treatment before surgery, n (%)
Steroids 46 (19) 33 (13) 13 (27) 0.03
Immunomodulators 114 (38) 93 (37) 21 (46) 0.34
Biologics 75 (24) 61 (24) 14 (28) 0.64
Treatment received at surgery, n (%)
Steroids 81 (25) 69 (27) 12 (23) 0.70
Immunomodulators 139 (44) 112 (43) 27 (52) 0.30
Biologics 11 (21) 27 (10) 11 (21) 0.60
Length of hospitalization, median (interquartile range), days 9 (7–14) 10 (7–14) 9 (8–14) 0.32
Post-operative complications, n (%) 82 (26) 68 (26) 14 (27) >0.99
Death 0 (0) 0 (0) 0 (0) –
Ileus 10 (12) 8 (12) 2 (14) 0.68
Anastomotic leak 22 (27) 18 (26) 4 (29) >0.99
Intra-abdominal abscess 23 (28) 20 (29) 3 (21) 0.75
Wound infection 29 (35) 24 (35) 5 (36) >0.99
Sepsis 3 (4) 3 (4) 0 (0) >0.99
Gastrointestinal bleeding 9 (11) 9 (13) 0 (0) 0.35
Extra-intestinal infections 10 (12) 6 (9) 4 (29) 0.06
Missing values were not included in the calculation of percentages.








Time to follow-up visit, median (interquartile range), days 33 (14–55) 32 (16–53) 38 (20–68) 0.31
Post-operative prophylaxis received, n (%) 208 (68) 169 (66) 39 (76) 0.19
Post-operative prophylaxis,a n (%)
Immunomodulators 141 (46) 111 (43) 30 (59) 0.04
Antibiotics 27 (9) 27 (11) 0 (0) 0.03
Aminosalycilates 39 (13) 30 (12) 9 (18) 0.25
None 99 (32) 87 (34) 12 (23) –
Colonoscopy performed within the first year, n (%) 181 (58) 154 (59) 27 (52) 0.39
Residual disease after surgery 22 (7) 18 (7) 4 (8) 0.77
Post-operative prophylaxis in patients with residual disease,a n (%)
Immunomodulators 8 (36) 6 (33) 2 (50) 0.60
Antibiotics 6 (27) 6 (33) 0 (0) 0.54
Aminosalycilates 8 (36) 6 (33) 2 (50) 0.60
None 6 (27) 5 (27) 1 (25) –
Colonoscopy scheduled in the first year in patient with residual disease, n (%) 12 (54) 10 (56) 2 (50) >0.99
aRecorded at discharge or at the first control visit.
Missing values were not included in the calculation of percentages.
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required hospitalization and 45 (15%) required re-intervention
in the 5 years of follow-up without significant differences be-
tween the PSG and the FSG (Table 4).
Discussion
In this study, we analysed the management and treatment out-
comes of 314 patients with CD who underwent ileocolonic
resection with ileocolonic anastomosis, 52 of whom had been
previously operated on. We found no differences in clinical
management between the PSG and the FSG except for the pro-
phylaxis with immunomodulators, which were more frequently
administered in the PSG. However, prophylactic therapy only
resulted in clinical benefit in patients in the FSG, showing a re-
duction in the rate of post-operative clinical recurrence at
5 years, which was not observed in the PSG.
Figure 1. Kaplan–Meyer curves for time to clinical recurrence in (A) patients who received prophylactic treatment and (B) patients who did not receive prophylactic
treatment








Post-operative clinical recurrence within the first year, n (%) 73 (23) 62 (24) 11 (21) 0.8
Rutgeert’s endoscopic score at 5 years after surgery, n (%) 0.85
i0–i1 116 (46) 100 (46) 16 (43)
i2 136 (54) 115 (53) 21 (57)
Hospitalizations within 5 years after surgery, n (%) 94 (30) 74 (28) 20 (39) 0.17
Re-interventions within 5 years after surgery, n (%) 45 (15) 38 (15) 7 (14) >0.99
Hospitalizations within 5 years after surgery in patients with residual disease, n (%) 15 (68) 12 (67) 3 (75) >0.99
Re-interventions within 5 years after surgery in patients with residual disease, n (%) 6 (27) 3 (17) 3 (75) 0.05
Figure 2. Kaplan–Meyer curves for time to clinical recurrence in (A) patients who underwent first surgery and (B) patients who underwent repetitive surgeries
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Similarly, there were no significant differences in the rates
of endoscopic, clinical or surgical recurrences between patients
operated on for the first time and those who had previous sur-
geries; whether the lack of differences could be due to more pro-
phylactic treatment received by the PSG mentioned above
would be a matter of debate. Our findings agree with a previous
report by Heimann et al. [18], who found that the rates of post-
operative clinical recurrence at 3 years after first and second (or
more) operations were similar (41% and 39%, respectively), al-
though the relapse rate increased significantly in patients with
three or more previous resections. The authors concluded that a
disease requiring multiple re-operations is more aggressive and
is more likely to result in complex resections, perioperative
blood transfusions and permanent ileostomy [18]. In our study,
there were very few patients with more than one re-operation,
so we were unable to corroborate these conclusions.
In our study, no differences in endoscopic procedures during
the first year after the index surgery were found between the
FSG and the PSG, probably reflecting the time at which the study
was performed (2007–2010). Accordingly, a previous publication
of the results of the PRACTICROHN study demonstrated a trend
towards an increased rate of endoscopies performed during the
first year after surgery from 2007 to 2010 [19].
Clinical guidelines suggest the use of prophylactic treatment
after ileocolonic intestinal resection in patients with at least one
risk factor for recurrence (evidence level 2). The drugs of choice to
prevent post-operative recurrence are thiopurines (evidence level
2) and anti-TNFs (evidence level 2). In our study, even though
most patients received prophylactic treatment (68%), the use of
prophylaxis in general and of immunomodulators in particular
was more frequent in re-operated patients. This may reflect the
urge for better prevention felt by the physicians in case of re-
operated patients, since previous surgeries have been suggested
to be a risk factor of poor outcomes in CD patients and have been
associated with poor prognosis [20]. Additionally, as reported in
the previous publication of the PRACTICROHN study [19], only
three patients received prophylaxis with anti-TNF and only one
patient on monotherapy, so we are not able to analyse the effect
of anti-TNF prophylaxis on clinical outcomes in this population.
Our multivariate analysis also showed that not receiving prophy-
laxis is a risk factor for post-operative clinical recurrence. In the
meta-analysis by Frolkis et al. [1], around one out of four patients
with CD underwent a second surgery within 5 years of their first
resection, but later the risk of a second surgery increased more
slowly (from 25% at 5 years to 35% at 10 years), hence strategies to
prevent re-interventions in the first 5 years after surgery may re-
sult in better disease outcomes. Our data showed that 45 (15%)
patients required re-intervention over the 5 years’ follow-up. The
lack of difference in the rates of re-interventions between the
FSG and the PSG observed in our study could be due to the insuf-
ficient size of the PSG, which could be too small to detect any dif-
ferences, as well as too short a follow-up period.
A small (7%–8%) and similar proportion of patients in the PSG
and the FSG had residual disease after resection. The multivariate
analysis showed that residual disease was associated with higher
risk of post-operative clinical recurrence. Interestingly, the man-
agement of these patients (prophylactic treatment, scheduled co-
lonoscopies) did not differ from the management of the rest.
However, the long-term outcomes among patients with residual
disease were substantially worse: the rates of hospitalizations and
re-interventions doubled those of the total patient population.
This observation held true both for patients with first surgery and
for those with previous surgeries. Besides, the rate of re-
interventions was significantly higher in re-operated patients
with residual disease, compared to those with first surgery and re-
sidual disease. However, the small number of patients and border-
line level of significance preclude drawing strong conclusions. Our
findings suggest that more research on management and out-
comes in these patients should be done and that specific manage-
ment algorithms may be needed for this patient population.
As the time from diagnosis to the first surgery is associated
with a higher probability of recurrence, this would imply that, in
some patients, an early surgery would be a good strategy to im-
prove long-term disease management, as shown in the study by
An et al. [21], which suggests that patients with ileocolonic CD
may have a more benign disease course if undergoing early surgi-
cal intervention, with fewer admissions to hospital and a trend
towards reduced overall operation rates, although it would be
necessary to design studies that explore this aspect in depth.
Our study has several limitations to consider. First, because
of the study’s retrospective design, the collected data were lim-
ited to those available from patients’ medical records. However,
the available data from clinical records were quite complete
and allowed drawing conclusions. Second, this was not a ran-
domized study, and therefore the decision to give a prophylactic
treatment for recurrence was not random, but a physician’s de-
cision according to the patient’s risk of recurrence. Similarly,
since this was an observational study, colonoscopy was not
done systematically in all patients, but according to routine
clinical practice and the physician’s decision. Another limita-
tion is that, although the overall sample size was quite large
(314 patients), only 52 (17%) patients referred previous surgeries.
Thus, some differences in characteristics, management or out-
comes may have stayed undetected because of insufficient sta-
tistical power. On the other hand, among the strengths of the
study, we could indicate a long (5 years’) follow-up and its real-
life, multicenter character that allows careful extrapolation
onto routine management of this challenging condition.
Table 5. Prognostic factors associated with post-operative recurrence using multivariate Cox regression analysis
Variable Coeficient ecoeficient P-value
Sex: woman –0.194 0.824 0.540
Age at the time of surgery 0.005 1.005 0.760
Disease behavior at the time of surgery: B2 6 P –0.704 0.494 0.220
Disease behavior at the time of surgery: B3 6 P –1.007 0.365 0.098
Prophylaxis: antibiotics 1.054 2.870 0.035
Prophylaxis: aminosalicylates 0.580 1.786 0.240
Prophylaxis: without prophylaxis 0.753 2.122 0.043
Residual disease: no –1.004 0.366 0.019
Time between diagnosis and first surgery 0.046 1.047 0.029
Smoker at the time of surgery –0.146 0.864 0.710
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In conclusion, in our study, patients with CD who had previ-
ous surgeries were more frequently treated with prophylactic
immunomodulators but had a similar rate of endoscopic, clini-
cal or surgical CD recurrence compared with patients operated
on for the first time. Although prophylactic treatment was ben-
eficial for preventing clinical recurrence in patients operated on
for the first time, it did not significantly reduce the risk of fur-
ther recurrence in patients with previous surgeries. This sug-
gests that a history of a previous surgery may be a poor
prognostic factor in patients with CD, and new strategies to pre-
vent recurrence in these patients may be needed.
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Barrio (Hospital Rio Ortega, Valladolid); Dr Angel Sierra
Hernández (Hospital Insular de Canarias, Las Palmas);
Dr Ingrid Ordás (Hospital Clinic, Barcelona), Dr Natalia
Borruel (Hospital Vall d’Hebrón, Barcelona), Dr Marı́a
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16.López-Sanromán A, Vera-Mendoza I, Domènech E et al.
Adalimumab vs azathioprine in the prevention of postopera-
tive Crohn’s disease recurrence: a GETECCU randomised trial.
J Crohns Colitis 2017;11:1293–301.
17.Bermejo F, Aguas M, Chaparro M et al. Recommendations
of the Spanish Working Group on Crohn’s Disease and
Ulcerative Colitis (GETECCU) on the use of thiopurines in
inflammatory bowel disease. Gastroenterol Hepatol 2018;41:
205–21.
18.Heimann TM, Greenstein AJ, Lewis B et al. Comparison of
primary and reoperative surgery in patients with Crohns
disease. Ann Surg 1998;227:492–5.
19.Domènech E, Garcia V, Iborra M et al. Incidence and manage-
ment of recurrence in patients with Crohn’s disease who
have undergone intestinal resection: the PRACTICROHN
study. Inflamm Bowel Dis 2017;23:1840–6.
20.Buisson A, Chevaux JB, Allen PB et al. Review article: the natu-
ral history of postoperative Crohn’s disease recurrence.
Letters to the Editors 2012;35:625–33.
21.An V, Cohen L, Lawrence M et al. Early surgery in Crohn’s
disease a benefit in selected cases. World J Gastrointest Surg
2016;8:492–500.






/gastro/article/7/6/411/5536322 by guest on 25 Septem
ber 2020
